LINE

Text:AAAPrint
Sci-tech

Oxford-AstraZeneca vaccine effective, but more analysis still needed: study

1
2020-12-09 08:51:39CGTN Editor : Li Yan ECNS App Download
Special: Battle Against Novel Coronavirus

A COVID-19 vaccine developed by the University of Oxford and AstraZeneca Plc provided protection against severe cases of the disease, though more analysis will be needed to see how well it works in older people, a peer-reviewed study showed.

The study results published on Tuesday by The Lancet medical journal showed that 10 cases of hospitalizations occurred among those given the placebo, suggesting the shot prevents the worst symptoms.

Bloomberg however reports that the vaccine's efficacy could not be assessed in older age groups because there weren't enough infections.

Older adults were recruited to the studies later that younger ones, so "they've had less time for cases to accrue in those age groups and for us to be able to measure an efficacy signal," said Andrew Pollard, director of the Oxford Vaccine Group. "The evidence we have so far on the immune response very much suggests that it's likely to be similar levels of protection across the ages."

The Bloomberg report also notes that even though the vaccine cannot match the efficacy delivered by front-runners Pfizer Inc. and Moderna Inc., it is expected to be cheaper and easier to deploy far and wide.

MorePhoto

Most popular in 24h

MoreTop news

MoreVideo

LINE
Back to top Links | About Us | Jobs | Contact Us | Privacy Policy
Copyright ©1999-2020 Chinanews.com. All rights reserved.
Reproduction in whole or in part without permission is prohibited.